Programs

Eiger is focused on the development and commercialization of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with highly unmet medical needs.

First-In-Class Therapies of Patients In Need

(Swipe to interact)

Targeted Indication	Drug	Orphan US / EU	Breakthrough Therapy	Rare Pediatric Disease*	Status
Hepatitis Delta Virus	Lonafarnib + Ritonavir			N/A	Phase 3
	Peginterferon Lambda			N/A	Phase 3 Ready
Progeria and Progeroid Laminopathies					NDA / MAA Filed PDUFA Date November 2020
Post-Bariatric Hypoglycemia	Avexitide			N/A	Phase 3 Ready
Congenital Hyperinsulinism					Phase 2

* Eligible for Priority Review Voucher (PRV)